The World Health Organization’s (WHO’s) 2023 Model Lists of Essential Medicines, published in July 2023, features key updates to the tuberculosis (TB) section. These complement current WHO recommendations for shorter treatment of multidrug-/rifampicin-resistant TB (MDR/RR-TB) and newer options to treat drug-susceptible TB in children and adolescents. WHO’s Global Tuberculosis Programme, with inputs from partners, proposed these changes to the EML based on the latest WHO recommendations and the current availability of TB medicines. Read more here.
top of page
Recent Posts
See AllA recent study on the incidence of MDR-TB in children and teens revealed that the prevalence has resurged. there was a 10 year drop from...
The Stop TB Partnership announced a major price reduction on bedaquiline. The cost per treatment course was slashed by over 50%,...
The shutdown and dismantling of USAID has had large ramifications for TB services. As one of the largest funding sources for TB, the...
bottom of page
Comments